On TRAC with charity donations
Cornish Regulatory Affairs Specialist raises £20,000 through volunteer project
The Camborne, UK-based company, which works with pharmaceutical manufacturers around the world, has donated £22,000 since launching a pioneering project in 2006 in which volunteers across Cornwall raised funds for a charity or community group in return for a 30-minute question and answer session.
The project was launched four years ago to enable pharmaceutical companies to get feedback on Patient Information Leaflets from members of the public, and gave everyone taking part the opportunity to raise money by donating £20 to a nominated charity or group.
More than 50 community groups such as Cornwall Blind Association, St Agnes Football Club, Truro Fencing Club, Cornwall Air Ambulance, and Camborne Bowling Association have all had their funds boosted by the volunteer scheme.
TRAC Director Sarah Trethowan said: ‘When we came up with the idea of running the volunteer project we really didn’t know if it would take off, but are absolutely thrilled that we have been able to donate £22,000 to good causes and community projects in Cornwall.
‘The beauty of the volunteer project was that not only did every person taking part in it raise £20 towards their nominated cause but by taking part they were also helping to improve the way pharmaceutical companies produce information leaflets, making them clearer and easier to understand.’
With the project now coming to an end, TRAC is continuing its charity work by becoming a member of Cornwall Community Foundation’s 100 Club, which has been launched to enable businesses in the county to help fund grassroots organisations and projects.
TRAC recently became the second firm in Cornwall to achieve a Silver Investors in People (IIP) standard. It also took top honours in the Graduate Development Category at the Cornwall Excellence in Business Training Awards 2010.
You may also like
Regulatory
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Manufacturing
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
